{"filing":{"accession_number":"0001493152-26-044454","cik":"0001014763","ticker":"AIMDW","company_name":"Ainos, Inc.","form":"8-K","filing_date":"2026-09-28","report_date":"2026-09-24","primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1014763/000149315226044454/form8-k.htm"},"events":[{"id":35314,"run_id":32522,"accession_number":"0001493152-26-044454","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Ainos entered into a Global Exclusive License Agreement with BioPhoenix on September 24, 2026, granting exclusive worldwide rights to develop and commercialize VELDONA® for Sjögren's Disease and Thrombocytopenia. The agreement includes an upfront fee of $600,000, potential additional payments up to ~$10 million, and 25% of net sublicensing revenue. This is a material strategic partnership that reduces Ainos' independent development burden while generating near-term and contingent revenue, but it is fundamentally an operational/strategic licensing transaction rather than a traditional M\u0026A activity, debt issuance, or other specifically-named event type.","company_name":"Ainos, Inc.","ticker":"AIMDW","filing_date":"2026-09-28","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":39328,"accession_number":"0001493152-26-044454","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Ainos entered into a Global Exclusive License Agreement with BioPhoenix on September 24, 2026, granting exclusive worldwide rights to develop and commercialize VELDONA® for Sjögren's Disease and Thrombocytopenia. The agreement includes an upfront fee of $600,000, potential additional payments up to ~$10 million, and 25% of net sublicensing revenue. This is a material strategic partnership that reduces Ainos' independent development burden while generating near-term and contingent revenue, but it is fundamentally an operational/strategic licensing transaction rather than a traditional M\u0026A activity, debt issuance, or other specifically-named event type.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T12:06:35.693595+00:00","company_name":"Ainos, Inc.","ticker":"AIMDW","filing_date":"2026-09-28"}]}